Results 251 to 260 of about 58,152 (283)

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

Vaccine, 2012
Katia Pauwels
exaly  

MVA as a vector for vaccines against HIV-1

Expert Review of Vaccines, 2004
Tomáš Hanke, Eung-Jun Im
exaly  

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins

Vaccine, 2004
Gerd Sutter, Peter Jm Openshaw, Yasemin Suezer   +2 more
exaly  

Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVA HIV

Vaccine, 2014
Uriel Y Moreno-Nieves, Françoise Barré-Sinoussi   +1 more
exaly  

MVA - Decomposition of Data Matrices

2023
Matthias Fengler, Petra Burdejova, Wolfgang Karl Härdle   +2 more
openaire   +1 more source

MVA Theory of the multinormal

Lennart John Baals, Matthias Fengler, Wolfgang Karl Härdle   +2 more
openaire   +1 more source

Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

Virus Research, 2006
Dolores Rodríguez, Mariano Esteban, Juan Ramon Rodríguez   +2 more
exaly  

Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity

Virus Research, 2018
Joanna Shisler
exaly  

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA

Vaccine, 1999
Stephen Whitehead, Bernard Moss, Linda S Wyatt   +2 more
exaly  

Albany MVA project.

2005
Edward B. Blanchard, Edward J. Hickling
openaire   +1 more source